Side Effects:
The common adverse reactions of Olaparib include:

Nausea, vomiting, loss of appetite, diarrhea, headache, unpleasant taste in the mouth, dizziness, or fatigue. Olaparib, also known as Olaparix (Olaparib 50mg), is a potent generic poly polymerase inhibitor indicated for the treatment of germline BRCA mutated (gBRCAm) advanced ovarian cancer that has undergone three or more prior lines of chemotherapy. It is the first PARP inhibitor approved for gBRCAm metastatic breast cancer.

Cost of Olaparib:
The cost of Olaparib 50mg is approximately 15094 USD per 120 Tablets. The generic Olaparib 50mg price in Indian online pharmacies is only 8% of the brand version.

Indications for Ovarian Cancer:
1. Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
2. Treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have received three or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for Olaparib 100mg.

Indication for Breast Cancer:
In patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer who have received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have received prior endocrine therapy or be considered inappropriate for endocrine therapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for Olaparib 100mg.

Dosage of Olaparib:
1. The recommended tablet dose is 300 mg taken orally twice daily with or without food.
2. Consider dose interruption or reduction for adverse reactions.
3. For moderate renal impairment (CLcr 31-50 mL/min), reduce the dose to 200 mg twice daily.

Serious Side Effects of Olaparib:
Olaparib may cause serious side effects, including bone marrow problems such as Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Symptoms of low blood cell counts should be monitored closely, and treatment may be stopped if necessary. Pneumonitis, a lung problem, may occur, leading to temporary or complete cessation of treatment.

Prescribing Information:
For detailed prescribing information, please request “FDA Prescribing Information” from our customer support.